Endometriosis affects roughly one in seven to one in ten women of reproductive age, and the pain it causes is among the most undertreated in medicine. The disease places endometrial-like tissue outside the uterus, where it responds to hormonal cycling, drives chronic inflammation, and produces pelvic pain, painful periods, pain during intercourse, and frequently bowel and bladder symptoms. Conventional treatment (hormonal suppression, NSAIDs, and surgery to remove lesions) helps many patients but leaves a large fraction with inadequate relief and low treatment satisfaction. That gap is the reason a substantial share of endometriosis patients have turned to cannabis on their own, and the reason the research base has grown quickly.
The evidence for cannabis in endometriosis is unusual in this field for how consistent it is across study types. Large patient surveys in Australia and New Zealand found that women using cannabis for endometriosis rated it among their most effective self-management strategies and frequently reduced other pain medications. A German-language survey of more than 900 patients found that around 17 percent used cannabis as a self-management method, rated it the single most effective strategy for reducing symptom intensity, and that roughly 90 percent were able to decrease their pain medication intake. Canadian app-tracking data found pelvic pain to be the most common reason for cannabis use sessions. The newest layer of evidence moves beyond survey data: the 2026 UK Medical Cannabis Registry study followed patients longitudinally, and the first dedicated randomized controlled trial of CBD for endometriosis pain has now reported results.
This page treats endometriosis pain as a Pain cluster condition with a cross-reference to women's health, because the mechanism is fundamentally a mixed-pain problem. The pain combines visceral nociceptive, inflammatory, neuropathic, and central-sensitization components, and that multi-mechanism character is what makes it both hard to treat conventionally and plausibly responsive to a broad-acting option like cannabis. The page covers the current evidence, the mechanism, the protocol, and the boundary that matters most: cannabis manages symptoms, it does not treat the disease.
What does the research actually show about cannabis for endometriosis pain?
The observational base is large and points in one direction. Sinclair and colleagues surveyed Australian and New Zealand women with endometriosis who used cannabis for symptom management and documented self-reported pain relief averaging well above the midpoint of a 0-to-10 scale, alongside reductions in pharmaceutical use. The companion Sinclair 2021 analysis in PLoS One examined the effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms, finding self-reported improvement not only in pain but in associated sleep and mood symptoms. A separate German-speaking survey of more than 900 patients reached compatible numbers: about 17 percent used cannabis, rated it the most effective self-management strategy at roughly 7.6 out of 10, and most reduced their pain medication.
The most important recent addition is longitudinal rather than cross-sectional. The Getter 2026 study drew on the UK Medical Cannabis Registry and followed 63 endometriosis patients prescribed cannabis-based medicinal products, measuring patient-reported outcomes at 1, 3, 6, 12, and 18 months. Pain-specific measures improved from baseline across the full follow-up period, and quality-of-life, anxiety, and sleep measures improved as well. Sixty-two adverse events were reported across 16 of the 63 patients, most of them mild. The authors were careful to note that an observational registry cannot establish causation, and framed the result as justification for the randomized trials that the field has lacked. The McLaren 2025 scoping systematic review pulled the literature together and reached the same structural conclusion: consistent observational signal, thin controlled evidence, clear need for trials.
Those trials are beginning to report. A dedicated randomized controlled trial of cannabidiol for endometriosis pain (registered as NCT04527003) posted results in 2025, marking the field's move from survey data toward controlled evidence. The Armour and Sinclair 2025 review in Expert Review of Endocrinology and Metabolism weighed the full picture and concluded that cannabis shows real promise for endometriosis symptom management while emphasizing that the controlled evidence is still early and that cannabis should sit alongside, not replace, established care. The honest summary for 2026 is that endometriosis has one of the more consistent observational evidence bases in cannabis pain medicine, that the first longitudinal and controlled data support the observational signal, and that the field is now in the phase of confirming with trials what patients have reported for a decade.
Why does the mixed-mechanism picture matter for endometriosis?
Endometriosis pain is built from several distinct pain types layered together, and understanding that layering explains both why it is hard to treat and why a broad-acting option draws interest. The lesions themselves produce visceral nociceptive pain, the deep, poorly localized pain characteristic of internal organs. The chronic inflammation around the lesions amplifies that signal and sensitizes the surrounding tissue. Where lesions infiltrate or compress nerves, particularly in deep infiltrating endometriosis, a neuropathic component is added, with the burning and shooting quality of nerve pain. And in long-standing disease, central sensitization develops: the central nervous system amplifies pain signals, lowering the threshold so that pain persists even where the peripheral disease burden does not fully account for it. This is the same nociplastic mechanism that defines fibromyalgia, and endometriosis patients with a strong central-sensitization component often share features with the nociplastic pain population.
The endocannabinoid system runs through several of these layers, which is the mechanistic basis for cannabis interest in endometriosis. The Lingegowda 2022 review in the Journal of Cannabis Research details the role of the endocannabinoid system in endometriosis pathophysiology: cannabinoid receptors are present in endometrial and lesion tissue, the system modulates the inflammation and pain signaling involved, and altered endocannabinoid tone has been observed in association with the disease. This places endometriosis loosely alongside the conditions in Russo's endocannabinoid deficiency hypothesis, with a more direct tissue-level rationale than the hypothesis offers for some other conditions, because the receptors and signaling are demonstrably present in the affected tissue itself.
For the patient, the practical implication is that no single mechanism target reliably resolves endometriosis pain, which is why hormonal suppression alone, or NSAIDs alone, or surgery alone, so often leaves residual pain. Cannabis engages the inflammatory, visceral, and central components together. That breadth is the plausible explanation for the consistency of the patient-reported benefit, and it is also why cannabis works as an adjunct rather than a replacement: it addresses the pain across its mechanisms while the gynecological care addresses the disease that generates the pain.
What is the protocol for endometriosis pain?
The starting protocol is 5mg THC paired with 10mg CBD, taken in the evening. Evening dosing fits the condition because pelvic pain and the sleep disruption it causes tend to concentrate at night, and because the CBD-leaning ratio addresses the inflammatory and anxiety components without daytime impairment. The CBD contributes anti-inflammatory effects relevant to the lesion-driven inflammation, and the THC addresses the visceral and central pain components. This balanced-to-CBD-leaning ratio sits between the THC-dominant neuropathic protocol and the higher-CBD fibromyalgia protocol, reflecting the mixed mechanism.
Because endometriosis pain cycles with menstruation in most patients, the timing strategy differs from steady chronic pain. Many patients benefit from dosing proactively in the days before an expected flare or menstruation rather than only reacting once pain has escalated. A patient who knows their cycle can begin or increase dosing ahead of the predictable pain window, which tends to work better than chasing an established flare. During the worst days, a daytime dose can be added to the evening baseline, keeping total daily THC modest (most patients who respond stay below 20mg daily).
For the acute, severe flares that endometriosis can produce, a traditional edible's 60-to-90-minute onset is slow. A faster-onset format (a nano-emulsion gummy or beverage) covers breakthrough pain better, while the slower traditional edible suits the steady baseline and the overnight window. Titrate the baseline over two to three weeks, and track not only pain intensity but the associated symptoms (sleep, mood, and the bowel and bladder symptoms that often accompany endometriosis), because improvement frequently shows up across that broader symptom cluster rather than in pain intensity alone.
The boundary on this protocol is firm: it is symptom management layered onto gynecological care, not a substitute for it. A patient whose pain is well controlled on cannabis still needs specialist follow-up for the disease, and any new or changing pelvic pain warrants evaluation rather than simply more cannabis. Endometriosis is associated with fertility implications and, rarely, with other pathology that pain relief can mask, so the disease itself stays under specialist management regardless of how well the symptoms respond.
How does cannabis fit alongside conventional endometriosis treatment?
Conventional endometriosis treatment works on the disease through two main routes: hormonal suppression (combined oral contraceptives, progestins, GnRH agonists and antagonists) to reduce the hormonal cycling that drives lesion activity, and surgery to remove or destroy lesions. NSAIDs address the inflammatory pain. These remain the backbone of care, and the cannabis evidence does not displace any of them. Cannabis adds a symptom-management layer for the pain that persists even with disease-directed treatment, which describes a large fraction of endometriosis patients given how often conventional treatment leaves residual pain.
The interaction considerations are manageable but real. CBD inhibits several cytochrome P450 enzymes, which can raise blood levels of medications metabolized by those enzymes; the effect is dose-dependent and most relevant above the CBD doses this protocol uses, but a patient on multiple medications should have the prescriber aware. The interaction between cannabis and hormonal treatments is not fully characterized in the literature, which is a reason for prescriber involvement rather than a documented hazard. Combined sedation matters for patients also using strong analgesics, sleep medications, or neuropathic-pain drugs like the gabapentinoids. As across the Pain cluster, the pattern that works is integration: cannabis added to the care plan with the treating gynecologist and any other prescribers aware of it, rather than a parallel self-managed regimen the clinical team does not know about.
The reason this integration matters more in endometriosis than in some other pain conditions is the disease's complexity and its fertility implications. Endometriosis management often involves decisions about hormonal treatment, surgical timing, and family planning that interact with each other, and pain that is well managed by cannabis is still pain generated by an active disease process. The medical-authority position is that cannabis earns a real place in endometriosis symptom management, supported by an observational base that is now being confirmed by longitudinal and controlled data, and that its place is firmly as part of comprehensive care rather than as an alternative to it.